NCT03798171 is a clinical trial in Peritoneal Dialysis Catheter Infection, sponsored by Tel-Aviv Sourasky Medical Center.

Who is sponsoring NCT03798171?

NCT03798171 is sponsored by Tel-Aviv Sourasky Medical Center.

What condition does NCT03798171 study?

NCT03798171 studies Peritoneal Dialysis Catheter Infection.

Is NCT03798171 still recruiting?

NCT03798171 is currently status unknown. Last updated 9 January 2019.

Last reviewed 2019-01-09 · How we verify

NCT03798171

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reduction of Exit Site Infection in Peritoneal Dialysis Patients

Status unknown Last updated 9 January 2019

What this trial tests

trial in Peritoneal Dialysis Catheter Infection in 80 participants. Status unknown.

Timeline

15 May 2018

Primary endpoint
15 May 2021

15 May 2021

Quick facts

Lead sponsor	Tel-Aviv Sourasky Medical Center
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	80
Start date	15 May 2018
Primary completion	15 May 2021
Estimated completion	15 May 2021
Sites	1 location across Israel

Conditions studied

Peritoneal Dialysis Catheter Infection — all drugs for Peritoneal Dialysis Catheter Infection →

Sponsor

Tel-Aviv Sourasky Medical Center

Who can join

Adults 18 to 99, any sex, with Peritoneal Dialysis Catheter Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In peritoneal dialysis patients, the presence of the catheter presents a risk of infection - exit site infection, tunnel infection or peritonitis. In our dialysis unit, we noticed a rise in exit-site infection associated with organisms derived from contaminated water. Therefore we decided to change the exit-site care in our unit. This is a prospective observational single center study, that compares exit-site infection rated in peritoneal dialysis patients before and after our policy change for exit-site care.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Tel-Aviv Sourasky Medical Center trials

Trials by the same sponsor.

NCT07380737 — Feasibility and Preliminary Effects of the Walking Tall App for Home-Based Gait Training in Parkinson's Disease: A Pilot · NA · recruiting
NCT07104136 — Improving Adherence to COPD Treatments in Primary Care · NA · enrolling by invitation
NCT07327021 — MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC · Phase 2 · recruiting
NCT07191249 — A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previousl · Phase 2 · not yet recruiting
NCT07235332 — Assessing Toxic Metal Exposure From Vegetarian/Vegan, Omnivorous, and Low-carb Diets in Israel. · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03798171 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tel-Aviv Sourasky Medical Center
Last refreshed: 9 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03798171.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing